Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + trastuzumab
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Capecitabine + trastuzumab is a combination therapy being evaluated by Fudan University, notably in the Phase II IRIS trial (NCT04252261), for the treatment of HER2-positive stage I breast cancer. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) that acts as an antimetabolite, inhibiting thymidylate synthase and disrupting DNA synthesis in rapidly dividing cancer cells. Trastuzumab is a humanized monoclonal antibody that targets the extracellular domain of the Human Epidermal Growth Factor Receptor 2 (HER2), blocking its activation and recruiting immune effector cells to mediate antibody-dependent cellular cytotoxicity (ADCC). This combination is being studied as a de-escalated adjuvant regimen to provide effective HER2-targeted therapy with reduced toxicity compared to standard multi-agent chemotherapy for patients with low-risk, early-stage disease.
- Brand names
- Herceptin
- Other names
- capecitabine and trastuzumabtrastuzumab plus capecitabine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + trastuzumab.